TACC3 and cancer: The pooled HRs of increased TACC3 expression on OS in patients with NSCLC, HCC and other cancers respectively were 2.02 (95% CI=1.37-2.96, P=0.000), 2.13 (95% CI=1.40-3.24, P=0.000) and 1.83 (95% CI=1.52-2.22, P=0.000).